Article in Science (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
24 authors.
Xiaojing Chen *Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0009-0002-8599-1992
Zhiyuan Mao *Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles (UCLA), Los Angeles, CA, USA.ORCID 0000-0002-5536-4691
E Motunrayo KolawoleDepartment of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA.
Margherita PersechinoDepartment of Biochemistry and Molecular Biophysics, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0003-1539-7621
Kevin M JudeDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-3675-5136
Masato OgishiDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0003-2421-7389
Kelvin C MoDepartment of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0009-0002-5494-6128
Jami McLaughlinDepartment of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles (UCLA), Los Angeles, CA, USA.
Donghui ChengDepartment of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles (UCLA), Los Angeles, CA, USA.
Xinyu XiangDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-8358-2960
Xinbo YangDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-1755-1349
Caitlin GeeDepartment of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles (UCLA), Los Angeles, CA, USA.
Shiqin LiuDepartment of Molecular and Medical Pharmacology, UCLA, Los Angeles, CA, USA.ORCID 0000-0001-5238-7137
Aerin YangDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-8704-0288
Matthias ObenausDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-5090-9162
Nan WangDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0001-6840-5336
Miyako NoguchiDepartment of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles (UCLA), Los Angeles, CA, USA.ORCID 0000-0003-0909-7358
Tanya StoyanovaDepartment of Molecular and Medical Pharmacology, UCLA, Los Angeles, CA, USA.
John K LeeDepartment of Molecular and Medical Pharmacology, UCLA, Los Angeles, CA, USA.ORCID 0000-0002-6570-2180
Zinaida GoodDepartment of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0003-2343-5771
Naomi R LatorracaDepartment of Biochemistry and Molecular Biophysics, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0002-8310-8708
Brian D EvavoldDepartment of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA.ORCID 0000-0002-3561-3494
Owen N WitteDepartment of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles (UCLA), Los Angeles, CA, USA.ORCID 0000-0003-4798-9621
K Christopher GarciaDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0001-9273-0278
Funding
UCLA SPORE IN PROSTATE CANCERP50CA092131 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REITER, ROBERT E · 2002 to 2023
$42.6M
Structural correlates of T cell receptor signalingR01AI103867 · NIAID · STANFORD UNIVERSITY · PI Kenan Christopher GARCIA · 2014 to 2026
$5.3M
Howard Hughes Medical InstituteNCI NIH HHS P50 CA092131NIAID NIH HHS R01 AI103867
6 · The paper itself
Abstract
T cells are often weakly responsive to tumor self-antigens because of central tolerance, constraining their ability to eliminate tumors. We exploited mechanical force to engineer a weakly reactive T cell receptor (TCR) specific for a nonmutated tumor-associated antigen (TAA), prostatic acid phosphatase (PAP). We identified a catch-bonding "hotspot" whose mutation enhanced T cell activity by increasing TCR-pMHC (peptide-major histocompatibility complex) bond lifetime while preserving physiological affinities and antigen fine specificities. T cells expressing these engineered TCRs showed vastly superior expansion in the tumor, effector phenotypes, and tumor elimination. Crystal structures and molecular dynamics simulations revealed a single amino acid mutation at the catch-bond hotspot primes the TCR for peptide interaction through water reorganization at the TCR-pMHC interface. Catch-bond engineering is a viable biophysically based strategy for transforming tolerized antitumor T cells into potent TCR-T cell therapy killers.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Overcoming T cell tolerance to tumor self-antigens through catch-bond engineering. · full record | OpenQuestion